What 'investigational' actually means

Before any drug can be tested in humans, its sponsor — usually a pharmaceutical company — must submit an Investigational New Drug (IND) applicationto the FDA. The IND includes the drug's manufacturing and chemistry data, results of animal studies, the proposed clinical protocol, and the credentials of the investigators who will run the studies. [1]

If the FDA does not object within 30 days, the drug becomes investigational — legally available for human study under the conditions of the IND. From that point until approval (which may never come), the drug exists in a regulatory limbo: studied in trials, but not for sale.

• Phase 1. First-in-human studies. Small groups (20-80 healthy volunteers, or in oncology, patients). Primary purpose: determine safety, tolerability, and how the body processes the drug. Duration: months.
• Phase 2. Larger studies (100-500 patients with the target condition). Primary purpose: assess efficacy at various doses and refine the safety profile. Multiple dose arms are common. Duration: months to a couple of years.
• Phase 3. Pivotal trials. Large (1,000-10,000+ patients), longer, often multi-center. Primary purpose: definitively confirm efficacy and safety at the dose intended for approval. Phase 3 results are usually the largest single component of the FDA submission package. Duration: 1-4 years.
• Phase 4. Post-approval studies, sometimes called post-marketing or surveillance studies. Primary purpose: characterize long-term safety, rare adverse events, and use in populations not well-represented in pivotal trials.

A drug remains investigational through Phases 1, 2, and 3. It only stops being investigational when the FDA approves it.

1. Pre-NDA / Pre-BLA meeting. The sponsor and FDA align on what the submission package must contain.
2. Filing. The sponsor submits a New Drug Application (NDA) — for small molecules — or a Biologics License Application (BLA) — for biologics, including peptides like retatrutide.
3. FDA filing acceptance. Within 60 days, the FDA decides whether the submission is complete enough to review. Acceptance starts the formal review clock.
4. Review. Standard review takes 10-12 months from acceptance. Priority review (for drugs treating serious conditions with significant improvement over existing therapy) cuts this to roughly 6-8 months.
5. Advisory committee, if convened. For novel drugs or contested questions, an external panel of independent experts advises the FDA. Their vote is non-binding but generally followed.
6. Action. The FDA either approves, issues a Complete Response Letter requesting more information, or rejects the application.
7. Labeling and launch. If approved, the final label is negotiated, manufacturing scales up, and commercial launch follows weeks-to-months later.

• Fast Track. More frequent FDA interactions during development. Available to drugs that fill an unmet medical need for a serious condition.
• Breakthrough Therapy. The strongest acceleration mechanism. Available when preliminary clinical evidence shows substantial improvement over available therapy. Includes intensive FDA guidance and rolling review of the submission package. [3]
• Accelerated Approval. Allows approval based on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required post-approval. Common in oncology and rare disease.
• Priority Review. Shortens the FDA review clock from 10-12 months to 6-8. Granted to drugs that, if approved, would be a significant improvement.

1. Clinical-trial enrollment. The primary mechanism. Trials are listed on ClinicalTrials.gov. Enrollment requires meeting eligibility criteria and informed consent.
2. Expanded access (compassionate use). Available in narrow circumstances when a patient has a serious condition with no satisfactory alternatives, the potential benefit justifies the risk, and the sponsor and investigator agree. Physician-initiated. [2]
3. Right to Try. Federal pathway (passed 2018) that allows certain terminally ill patients to request investigational drugs directly from sponsors without FDA involvement. Sponsors are not obligated to provide.

Products marketed online as "research peptides" or "not for human use" versions of investigational drugs are not legitimate access channels. They are unregulated, of unverified identity and purity, and frequently involve illegal importation. They are not the same molecule being studied in registered trials.

• The drug receives a brand name and an approved label describing its indications, dosing, contraindications, and warnings.
• Licensed clinicians can prescribe it for the approved indication.
• Pharmacies can dispense it. Insurance plans negotiate coverage decisions, often slowly.
• Phase 4 surveillance begins. Real-world data accumulates. Rare adverse events that were too infrequent to detect in Phase 3 may surface.
• Off-label prescribing becomes legally possible — clinicians may prescribe an approved drug for indications other than the FDA-approved one, at their discretion.

• EMA (European Union) — runs the Centralised Procedure, leading to approval valid across all EU member states. Reviewed by the CHMP committee. Standard timelines roughly comparable to FDA priority review.
• MHRA (United Kingdom) — independent post- Brexit, but generally tracks EMA closely.
• PMDA (Japan) — separate review, with emphasis on local clinical data.
• Health Canada, TGA (Australia), NMPA (China) — each has its own review pathway, often referencing FDA or EMA decisions.

For most large pharmaceutical companies, US, EU, and UK filings happen within months of each other. National approvals in smaller markets may follow over the next 1-3 years.